Sugi Predict

Sugi Predict / Compounds / SCHEMBL1782181

SCHEMBL1782181

SCHEMBL1782181

COc1cc(C(=O)N2CCCC2)ccc1N

nearest known ligand 0.64

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 7/20 0.64
▸ L3MBTL1 Q9Y468 2/20 0.64
▸ HSD17B10 Q99714 2/20 0.61
▸ HSD11B1 P28845 3/20 0.55
▸ ALDH1A1 P00352 6/20 0.53
▸ POLB P06746 1/20 0.53
▸ CYP2C19 P33261 1/20 0.53
▸ MEN1 O00255 1/20 0.53
▸ KMT2A Q03164 1/20 0.53
▸ GLA P06280 1/20 0.50
▸ CYP3A4 P08684 1/20 0.50
▸ MAPT P10636 1/20 0.50
▸ CYP2C9 P11712 1/20 0.50
▸ TSHR P16473 1/20 0.50
▸ DUSP3 P51452 1/20 0.50
▸ GFER P55789 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30870987 1.00 HPGD (0.64) HPGDL3MBTL1HSD17B10HSD11B1ALDH1A1
SCHEMBL13575486 0.98 HPGD (0.63) HPGDL3MBTL1HSD17B10HSD11B1ALDH1A1
SCHEMBL30871381 0.97 HPGD (0.60) HPGDL3MBTL1HSD17B10HSD11B1ALDH1A1
SCHEMBL15651739 0.97 HPGD (0.60) HPGDL3MBTL1HSD17B10HSD11B1ALDH1A1
SCHEMBL15880929 0.94 ALDH1A1 (0.59) HPGDL3MBTL1HSD17B10HSD11B1ALDH1A1
SCHEMBL29531076 0.88 POLB (0.63) HPGDL3MBTL1HSD11B1ALDH1A1POLB
SCHEMBL29531267 0.88 PKM (0.57) HPGDL3MBTL1HSD17B10HSD11B1ALDH1A1
SCHEMBL12312321 0.88 ALDH1A1 (0.54) HPGDL3MBTL1HSD17B10HSD11B1ALDH1A1
SCHEMBL520418 0.88 POLB (0.63) HPGDL3MBTL1HSD11B1ALDH1A1POLB
SCHEMBL11300155 0.88 PKM (0.57) HPGDL3MBTL1HSD17B10HSD11B1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4605392-A1 METHODS FOR TREATING CANCER Antares Therapeutics, Inc. (US) 2025-08-27 — — EP disclosed
WO-2024086809-A1 METHODS FOR TREATING CANCER SCORPION THERAPEUTICS, INC. (US) 2024-04-25 — — WO disclosed
US-11396508-B2 TYK2 inhibitors and uses thereof NIMBUS LAKSHMI, INC. (US) 2022-07-26 — — US disclosed
US-20220073527-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2022-03-10 — — US disclosed
US-11220508-B2 TYK2 inhibitors and uses thereof NIMBUS LAKSHMI, INC. (US) 2022-01-11 — — US disclosed
US-11174265-B2 — — 2021-11-16 — — US disclosed
US-20210230163-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-07-29 — — US disclosed
EP-3848370-A2 TYK2 INHIBITORS AND USES THEREOF Nimbus Lakshmi, Inc. (US) 2021-07-14 — — EP disclosed
US-20210094948-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-04-01 — — US disclosed
US-20210094948-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-04-01 — — US disclosed
US-20140194418-A1 BICYCLIC CARBOXAMIDE INHIBITORS OF KINASES ABBVIE INC. (US) 2014-07-10 — — US disclosed
US-20140155389-A1 BICYCLIC INHIBITORS OF ALK ABBVIE INC. (US) 2014-06-05 — — US disclosed
WO-2014060113-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2014-04-24 — — WO disclosed
WO-2014060112-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2014-04-24 — — WO disclosed
EP-2665724-A1 BICYCLIC INHIBITORS OF ALK AbbVie Inc. (US) 2013-11-27 — — EP disclosed
WO-2012097682-A1 BICYCLIC INHIBITORS OF ALK ABBOTT LABORATORIES (US) 2012-07-26 — — WO disclosed
US-20110118238-A1 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS ASTRAZENECA AB (SE) 2011-05-19 — — US disclosed
EP-2212326-A1 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS AstraZeneca AB (SE) 2010-08-04 — — EP disclosed
WO-2009024824-A1 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS ASTRAZENECA AB (SE) 2009-02-26 — — WO disclosed
WO-2007095188-A2 DIHYDRODIAZEPINES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-08-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11220508-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 HPGD 4476/4885L3MBTL1 914/4885HSD17B10 2692/4885
US-20210094948-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 HPGD 4476/4885L3MBTL1 914/4885HSD17B10 2692/4885
US-20110118238-A1 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS BUB1, BUB1B, TTBK1 HPGD 4223/4885L3MBTL1 2292/4885HSD17B10 4313/4885
US-20210230163-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 HPGD 4476/4885L3MBTL1 914/4885HSD17B10 2692/4885
US-11174265-B2 — TYK2, JAK2, JAK1 HPGD 4569/4885L3MBTL1 804/4885HSD17B10 2324/4885
US-20140155389-A1 BICYCLIC INHIBITORS OF ALK ALK, ABL1, BOD1L1 HPGD 3413/4885L3MBTL1 470/4885HSD17B10 1999/4885
US-11396508-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 HPGD 4476/4885L3MBTL1 914/4885HSD17B10 2692/4885
US-20220073527-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 HPGD 4476/4885L3MBTL1 914/4885HSD17B10 2692/4885
US-20140194418-A1 BICYCLIC CARBOXAMIDE INHIBITORS OF KINASES ALK, BRAF, BMX HPGD 3941/4885L3MBTL1 2374/4885HSD17B10 3421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.